Chicago, ILNCT07109219Now EnrollingIRB Ready

Acute Lymphoblastic Leukemia Clinical Trial in Chicago, IL

Access cutting-edge acute lymphoblastic leukemia treatment through this phase 1/2 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access acute lymphoblastic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute lymphoblastic leukemia treatment provided free

Apply for This Chicago Location

Check if you qualify for this acute lymphoblastic leukemia clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Acute Lymphoblastic Leukemia Study in Chicago

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

16 years old in Module 1 (US only: ≥18year)
12 years old in Module 2 2\. Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022).
Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts \> 5% or reappearance of blasts in PB)
Module 1 (DE): Ph(-) B-ALL and Ph(+) B-ALL - R/R
Backfill of Module 1 and Module 2 (DO): R/R Ph(-) B-ALL 3\. Performance status (ECOG ≤ 2; KPS ≥ 50; LPS ≥ 50) 4\. Peripheral lymphoblast count \< 10,000/µL (may receive cytoreduction prior to C1D1 per protocol-specified criteria) 5\. At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. Participants who have received prior CD22 targeted therapies are eligible.
Ph+ B-ALL (Module 1 DE only): intolerant to or have contraindications to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI 6\. Prior DLI \>4 weeks, prior cell therapy or autoHSCT \>8 weeks, alloHSCT \>12 weeks

Exclusion Criteria

Burkitt lymphoma and leukemia
Isolated extramedullary disease; Active testicular or CNS (\> CNS1) involvement
Unresolved non-heme toxicities Grade ≥ 2 (except alopecia, stable Grade ≤ 2 neuropathy, vitiligo, endocrine disorders controlled with therapy)
History of drug-induced non-infectious ILD/pneumonitis requiring oral or IV steroids or supplemental oxygen or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Prior/concomitant therapy
Cytotoxic treatment within 14 days (except ALL maintenance medications or cytoreduction)
Biologic (immuno-oncology) treatment within 28 days or 5 half-lives (whichever is shorter)
Non-CNS radiation within 2 weeks \& CNS radiation within 4 weeks
Medications known to prolong QTc and/or associated with Torsades de Pointes within 5 half-lives
Strong inhibitors of CYP 3A4 within 14 days or 5 half-lives (whichever is longer)
Investigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer. If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07109219) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphoblastic Leukemia Treatment Options in Chicago, IL

If you're searching for acute lymphoblastic leukemia treatment options in Chicago, IL, this clinical trial (NCT07109219) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Chicago, IL

See all leukemia clinical trials recruiting in Chicago — not just this study.

Browse Leukemia Trials in Chicago →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsHeart Attack TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL